Xanthomicrol: Effective therapy for cancer treatment

Comparative Evaluation of Cytotoxic and Apoptotic Effects of Natural Compounds in SH-SY5Y Neuroblastoma Cells in Relation to Their Physicochemical Properties

The cytotoxic and apoptotic properties of four bioactive natural compounds, the prenylated α-pyronephloroglucinol heterodimer arzanol (ARZ), the methoxylated flavones eupatilin (EUP) and xanthomicrol (XAN), and the sesquiterpene zerumbone (ZER), were compared in SH-SY5Y human neuroblastoma cells to assess their potential as neuroblastoma-specific therapeutics. EUP, XAN, and ZER (2.5-100 μM) exerted marked significant cytotoxicity (MTT assay) and morphological changes after 24 h of incubation, following the order XAN > ZER > EUP > ARZ (no toxic effect). The propidium iodide fluorescence assay (PI, red fluorescence) and NucView® 488 assay (NV, green fluorescence) evidenced a significant increase in the apoptotic cell number, vs. controls, in SH-SY5Y cells pre-incubated for 2 h with the compounds, in the following order of apoptotic potency: XAN > EUP > ZER > ARZ. The PubChem database and freely accessible web tools SwissADME, pkCSM-pharmacokinetics, and SwissTargetPrediction were used to assess the physicochemical/pharmacokinetic properties and potential protein targets of the compounds. At 50 μM, a positive correlation (r = 0.917) between values of % viability reduction and % human intestinal absorption (bioavailability) was observed, indicating a marked contribution of compound membrane permeability to cytotoxicity in SH-SY5Y cells. The capacity of compounds to induce apoptosis emerged as inversely correlated to the computed lipophilicity (r = -0.885).

Phytochemical screening, UPLC analysis, evaluation of synergistic antioxidant and antibacterial efficacy of three medicinal plants used in Kinshasa, D.R. Congo

Plant extracts are used worldwide due to their biologically active compounds, which support food preservation and help combat various diseases through their antimicrobial and antioxidant properties. In the capital city of the Democratic Republic of the Congo, an ethnobotanical survey revealed the use of Dysphania ambrosioides (L.) Mosyakin & Clemants, Ocimum gratissimum L. and Tetradenia riparia (Hochst.) Codd, often in combination, for treating oral microbial diseases. While these plants have been widely studied individually; their combined potential has not been investigated. The present research aims to explore the phytochemical composition, the synergistic antimicrobial, and antioxidant potential of different extracts from these three mentioned plants. Phytochemical composition of the decocted and percolated extracts from the three plants was determined using qualitative analysis and the ultra-performance liquid chromatography quadrupole time of flight tandem mass spectrometry (UPLC-QTOF-MS). Antimicrobial activity was assessed using the broth dilution method, while antioxidant activity was evaluated using the DPPH method. For the antimicrobial studies, the decocted and percolated extracts were tested against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Qualitative phytochemical analysis revealed the presence of alkaloids, saponins, flavonoids, iridoids, and anthraquinones in all the plant extracts. The methanolic extract of T. riparia exhibited the highest phenolic content (299.146 ± 0.143 mg GAE/g extract), while O. gratissimum had the highest flavonoid content (138.256 ± 0.277 mg QE/g extract). UPLC analysis identified several metabolites in the plant extracts including rosmarinic acid, cirsimaritin, xanthomicrol and kaempferol derivatives. Rosmarinic acid was consistently identified across all the plant extract combinations, while other flavonoids such as apigenin 7-glycosides, kaempferitin and luteolin 7-O-glucoside, were detected in specific plant extract combinations. The decocted plant extracts exhibited higher antioxidant activity than the percolated extracts, with O. gratissimum showing the highest antioxidant activity (11.744 ± 0.584 µg/mL), followed by T. riparia (12.916 ± 0.972 µg/mL). The extract combinations from O. gratissimum and T. riparia demonstrated synergistic antioxidant activity (CI = 0.57). Amongst all extracts, the highest antibacterial activity was observed in the decocted extracts of O. gratissimum and T. riparia against S. aureus (MIC = 500 µg/mL), with their combination showing additive antibacterial activity (FICI = 1). The aim of this study was primarily to evaluate the combinatory potential of these three plants as reliable sources of antimicrobials and antioxidants for the treatment of various microbial diseases in the future. The study provides evidence of the synergistic antioxidant and antibacterial potential of O. gratissimum and T. riparia. These results suggest that these plant extracts are promising sources of natural antimicrobial and antioxidant agents, with potential application in the pharmaceutical and food industries for combating several infectious diseases.

Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view

MicroRNAs (miRNAs) are a group of small non-coding RNAs and play an important role in controlling vital biological processes, including cell cycle control, apoptosis, metabolism, and development and differentiation, which lead to various diseases such as neurological, metabolic disorders, and cancer. Chemotherapy consider as gold treatment approaches for cancer patients. However, chemotherapeutic is one of the main challenges in cancer management. Doxorubicin (DOX) is an anti-cancer drug that interferes with the growth and spread of cancer cells. DOX is used to treat various types of cancer, including breast, nervous tissue, bladder, stomach, ovary, thyroid, lung, bone, muscle, joint and soft tissue cancers. Also recently, miRNAs have been identified as master regulators of specific genes responsible for the mechanisms that initiate chemical resistance. miRNAs have a regulatory effect on chemotherapy resistance through the regulation of apoptosis process. Also, the effect of miRNAs p53 gene as a key tumor suppressor was confirmed via studies. miRNAs can affect main biological pathways include PI3K pathway. This review aimed to present the current understanding of the mechanisms and effects of miRNAs on apoptosis, p53 and PTEN/PI3K/Akt signaling pathway related to DOX resistance.

The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells

BACKGROUND

Oxaliplatin is one of the main therapeutics in colorectal cancer (CRC) chemotherapy. However, in light of multidrug resistance (MDR) phenotype development, the efficacy of oxaliplatin has decreased. This study aimed to assess the potential therapeutic effect of melatonin in oxaliplatin combination therapy for drug-resistant colorectal cancer cells.

METHODS AND RESULTS

Initially, the oxaliplatin-resistant cell line was created of LS174T (LS174T/DR) by using the oxaliplatin IC50 concentration and resting cycles. MTT assays and flow cytometry were applied for assessing cell viability and apoptotic cells. The mRNA expression level of Bax, Bcl2, MT1, MT2, and ABCB1 as well as protein levels of ABCB1, Bcl2, BAX were measured by the qRT-PCR and western blot techniques respectively. P-gp activity was assessed by Rho123 staining. The IC50 concentration of oxaliplatin in resistant cells was increased from 500.7 ± 0.2 nM to 7119 ± 0.1 nM. Bcl2, MT1, MT2, and ABCB1 mRNA plus protein expression levels of Bcl2 and ABCB1 were significantly reduced in resistant cells, along with a marked increase in Bax mRNA and protein levels compared to parental cells. Rho 123 staining revealed a marked reduction in P-gp activities in the combination-treated group compared to the oxaliplatin-treated group.

CONCLUSIONS

The results of cytotoxicity assays, MTT, and flow cytometry revealed that the combination of melatonin and oxaliplatin exerts synergistic effects on induction of oxaliplatin's cytotoxicity in CRC. Our research suggests that combining the treatments of melatonin and oxaliplatin may be considered as a new approach to overcoming oxaliplatin resistance in CRC patients.

Therapeutic Approaches in Pancreatic Cancer: Recent Updates

Cancer is a significant challenge for effective treatment due to its complex mechanism, different progressing stages, and lack of adequate procedures for screening and identification. Pancreatic cancer is typically identified in its advanced progression phase with a low survival of ~5 years. Among cancers, pancreatic cancer is also considered a high mortality-causing casualty over other accidental or disease-based mortality, and it is ranked seventh among all mortality-associated cancers globally. Henceforth, developing diagnostic procedures for its early detection, understanding pancreatic cancer-linked mechanisms, and various therapeutic strategies are crucial. This review describes the recent development in pancreatic cancer progression, mechanisms, and therapeutic approaches, including molecular techniques and biomedicines for effectively treating cancer.